CJC-1295 + Ipamorelin + GHRP-6: GH Secretagogue Max
An advanced triple-secretagogue stack designed to maximally stimulate endogenous GH release through three complementary mechanisms. CJC-1295 extends GHRH signalling, Ipamorelin provides selective ghrelin-receptor stimulation with a clean side-effect profile, and GHRP-6 adds additional pulse amplitude alongside appetite stimulation. This combination is popular in performance communities seeking the highest attainable GH output without exogenous HGH.
Safety Notes
All three are unapproved research compounds. GHRP-6 commonly causes significant appetite stimulation and transient cortisol and prolactin elevation, distinguishing it from the cleaner side-effect profile of Ipamorelin. Risks overlap with chronically elevated GH: water retention, joint discomfort, and potential insulin resistance. Contraindicated in active or hormone-sensitive malignancies; no formal safety data exists for this triple combination.
Peptides in This Stack
- 1CJC-1295Fat Loss
Provides the sustained GHRH signal backbone of the stack, setting the hormonal stage for the additional secretagogues to stack upon by extending baseline GH pulse duration.
- 2IpamorelinPerformance
Adds selective ghrelin-receptor stimulation with a minimal side-effect profile, contributing to GH pulse amplitude without introducing meaningful cortisol or prolactin elevation.
- 3GHRP-6Performance
Contributes additional GH pulse amplitude and appetite stimulation via ghrelin signalling, aimed at maximising total GH output; the appetite side effect can be a deliberate tool during caloric surplus phases.
Research References
Emerging
- Prolonged stimulation of GH and IGF-I secretion by CJC-1295J Clin Endocrinol Metab 2006 · PMID 16822960Per-component source only — no combination study exists
- Ipamorelin, the first selective growth hormone secretagogueEur J Endocrinol 1998 · PMID 9849822Per-component source only — no combination study exists
Preliminary
- On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormoneEndocrinology 1984 · PMID 6325883Foundational discovery paper — no combination study exists
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.